GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (OTCPK:ACORQ) » Definitions » 3-Year Revenue Growth Rate

Acorda Therapeutics (Acorda Therapeutics) 3-Year Revenue Growth Rate : -37.00% (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Acorda Therapeutics 3-Year Revenue Growth Rate?

Acorda Therapeutics's Revenue per Share for the three months ended in Mar. 2024 was $16.34.

During the past 12 months, Acorda Therapeutics's average Revenue per Share Growth Rate was -9.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was -37.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was -39.10% per year. During the past 10 years, the average Revenue per Share Growth Rate was -23.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Acorda Therapeutics was 73.50% per year. The lowest was -59.70% per year. And the median was -2.50% per year.


Competitive Comparison of Acorda Therapeutics's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acorda Therapeutics's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Acorda Therapeutics's 3-Year Revenue Growth Rate falls into.



Acorda Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Acorda Therapeutics  (OTCPK:ACORQ) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Acorda Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Acorda Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Acorda Therapeutics (Acorda Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.
Executives
Thomas M. Burns director 2910 SEVENTH STREET, BERKELEY CA 94710
Ron Cohen officer: CEO and President C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
John Varian director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Michael A Gesser officer: Chief Financial Officer 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Neil S. Belloff officer: General Counsel 11 RADNOR LANE, MAHOPAC NY 10541
Kerry M Clem officer: Chief Commercial Officer 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Morales officer: Interim PAO & PFO 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Jane Wasman officer: Exec V Pres, Gen Cnsl & Sec C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella officer: Exec. VP-Commercial Dvlpmnt C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David Lawrence officer: Chief Financial Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Capital Management Lp 10 percent owner 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Lorin Randall director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Burkhard Blank officer: Chief Medical Officer C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Management, Inc. 10 percent owner 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Matthew Sirovich 10 percent owner C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123

Acorda Therapeutics (Acorda Therapeutics) Headlines

From GuruFocus

Q2 2020 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024

Acorda Therapeutics Inc Q&A Call Transcript

By GuruFocus Research 02-06-2024

Q1 2022 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024

Q2 2019 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024

Acorda Therapeutics Inc Virtual Q&A Call Transcript

By GuruFocus Research 02-06-2024

Q3 2023 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024

Q2 2023 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024

Q3 2021 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024

Q3 2020 Acorda Therapeutics Inc Earnings Call Transcript

By GuruFocus Research 02-06-2024